About Event

Overcome the Translational Challenges of Developing mRNA, DNA & Viral Vector-Based Vaccines for Infectious Diseases

It has been a landmark year for gene-based vaccines once again, with the development of the first mRNA COVID-19 booster doses, approval of the world’s first DNA-based vaccine for human use, and the continued clinical development of viral vector-based vaccines.

Attend this event to:

Meet In-Person

Reunite with the vaccine community to foster new relationships, collaborations, and take advantage of those all-important face-to-face networking connections

Dedicated Streams

No matter what stage of vaccine development, whether its early discovery and pipeline evaluation or clinical development and IND-filing, gain access to content that’s right for you to ensure you remain competitive within the rapidly growing genetic vaccine market

Content Beyond COVID-19

With industry rapidly expanding mRNA, DNA, and viral vector-based technology beyond COVID-19 to other infectious diseases, gain access to novel and unpublished case studies and discover how newer platforms such as srRNA and AAV vectors hold great promise for previously unmet infections.